Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1815, Issue 1, 2011, Pages 115-133

  Okoh, Victor ^a   Deoraj, Alok ^a   Roy, Deodutta ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Breast cancer; Estrogen; ROS; Signal transduction

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; EBSELEN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESNA; MITOGEN ACTIVATED PROTEIN KINASE; PENTOXIFYLLINE; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; RAF PROTEIN; RALOXIFENE; REACTIVE OXYGEN METABOLITE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR NRF1;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; GENE TARGETING; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 78650555076     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.10.005     Document Type: Review

References (331)

1. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003, 86:225.
2. Boukari K., Ciampi M.L., Guiochon-Mantel A., Young J., Lombes M., Meduri G. Human fetal testis: source of estrogen and target of estrogen action. Hum. Reprod. 2007, 22:1885.
3. Hess R.A., Bunick D., Bahr J. Oestrogen, its receptors and function in the male reproductive tract - a review. Mol. Cell Endocrinol. 2001, 178:29.
4. Jiang N.S., Ryan R.J., Albert A. Radioimmunoassay of serum estrogen. Clin. Chem. 1973, 19:740.
5. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001, 344:276.
6. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988, 48:246.
7. Roy D., bul-Hajj Y.J. Estrogen-nucleic acid adducts: guanine is major site for interaction between 3, 4-estrone quinone and COIII gene. Carcinogenesis 1997, 18:1247.
8. Roy D., Colerangle J.B., Singh K.P. Is exposure to environmental or industrial endocrine disrupting estrogen-like chemicals able to cause genomic instability?. Front Biosci. 1998, 3:d913-d921.
9. Roy D., Cai Q., Felty Q., Narayan S. Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J. Toxicol. Environ. Health B Crit Rev. 2007, 10:235.
10. Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 1993, 15:48.
11. Xu W.H., Xiang Y.B., Ruan Z.X., Zheng W., Cheng J.R., Dai Q., Gao Y.T., Shu X.O. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int. J. Cancer 2004, 108:613.
12. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita H.B., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils C.H., Gonzalez C.A., Gurrea A.B., Critselis E., Khaw K.T., Krogh V., Lahmann P.H., Nagel G., Olsen A., Onland-Moret N.C., Overvad K., Palli D., Panico S., Peeters P., Quiros J.R., Roddam A., Thiebaut A., Tjonneland A., Chirlaque M.D., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2005, 97:755.
13. Zucchetto A., Serraino D., Polesel J., Negri E., De P.A., Dal M.L., Montella M., La V.C., Franceschi S., Talamini R. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur. J. Cancer Prev. 2009, 18:316.
14. Arteaga E., Villaseca P., Bianchi M., Rojas A., Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003, 10:142.
15. Bocchinfuso W.P., Korach K.S. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary. Gland. Biol. Neoplasia. 1997, 2:323.
16. Castagnetta L., Granata O.M., Cocciadiferro L., Saetta A., Polito L., Bronte G., Rizzo S., Campisi I., Agostara B., Carruba G. Sex steroids, carcinogenesis, and cancer progression. Ann. N. Y. Acad. Sci. 2004, 1028:233.
17. Liehr J.G., Roy D., Gladek A. Mechanism of inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by vitamin C. Carcinogenesis 1989, 10:1983.
18. Roy D., Liehr J.G. Inhibition of estrogen-induced kidney carcinogenesis in Syrian hamsters by modulators of estrogen metabolism. Carcinogenesis 1990, 11:567.
19. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Post-Menopausal Hormonal Therapy 1999, 399-530. WHO.
20. Federal Report on Carcinogens, National Toxicology Program (NTP), National Toxicology Program (NTP), 2002, pp. 177283-77285.
21. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab 1996, 81:1460.
22. Vermeulen A., Deslypere J.P., Paridaens R., Leclercq G., Roy F., Heuson J.C. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 1986, 22:515.
23. Bocchinfuso W.P., Hively W.P., Couse J.F., Varmus H.E., Korach K.S. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res. 1999, 59:1869.
24. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr. Rev. 1999, 20:358.
25. Colletta A.A., Wakefield L.M., Howell F.V., van Roozendaal K.E., Danielpour D., Ebbs S.R., Sporn M.B., Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer 1990, 62:405.
26. Jordan V.C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat. 1994, 31:41.
27. Charlier C., Colin C., Merville M.P., Gielen J., Lambotte R., Plomteux G., Castronovo V. Tamoxifen in the treatment of breast cancer. J. Gynecol. Obstet. Biol. Reprod. (Paris) 1994, 23:751.
28. Felty Q., Xiong W.C., Sun D., Sarkar S., Singh K.P., Parkash J., Roy D. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005, 44:6900.
29. Sastre-Serra J., Valle A., Company M.M., Garau I., Oliver J., Roca P. Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic. Biol. Med. 2010, 48:506.
30. Felty Q., Singh K.P., Roy D. Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 2005, 24:4883.
31. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., Roy D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J. Natl. Cancer Inst. Monogr 2000, 75.
32. Roy D., Liehr J.G. Estrogen, DNA damage and mutations. Mutat. Res. 1999, 424:107.
33. Roy D., Singh K.P. Estrogen-induced genetic alterations and breast, endometrial, testicular and prostate cancers. Current Genomics 2004, 5:245.
34. Sarabia S.F., Zhu B.T., Kurosawa T., Tohma M., Liehr J.G. Mechanism of cytochrome P450-catalyzed aromatic hydroxylation of estrogens. Chem. Res. Toxicol. 1997, 10:767.
35. Raftogianis R., Creveling C., Weinshilboum R., Weisz J. Estrogen metabolism by conjugation. J. Natl. Cancer Inst. Monogr 2000, 113.
36. Roy D., Bernhardt A., Strobel H.W., Liehr J.G. Catalysis of the oxidation of steroid and stilbene estrogens to estrogen quinone metabolites by the beta-naphthoflavone-inducible cytochrome P450 IA family. Arch. Biochem. Biophys. 1992, 296:450.
37. Zhang F., Bolton J.L. Synthesis of the equine estrogen metabolites 2-hydroxyequilin and 2-hydroxyequilenin. Chem. Res. Toxicol. 1999, 12:200.
38. Markides C.S., Roy D., Liehr J.G. Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch. Biochem. Biophys. 1998, 360:105.
39. Chang M., Zhang F., Shen L., Pauss N., Alam I., van Breemen R.B., Blond S.Y., Bolton J.L. Inhibition of glutathione S-transferase activity by the quinoid metabolites of equine estrogens. Chem. Res. Toxicol. 1998, 11:758.
40. Hachey D.L., Dawling S., Roodi N., Parl F.F. Sequential action of phase I and II enzymes cytochrome p450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res. 2003, 63:8492.
41. Cavalieri E., Chakravarti D., Guttenplan J., Hart E., Ingle J., Jankowiak R., Muti P., Rogan E., Russo J., Santen R., Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766:63.
42. Li J.J., Li S.A. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc. 1987, 46:1858.
43. Liehr J.G., Fang W.F., Sirbasku D.A., ri-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem. 1986, 24:353.
44. Zhu B.T., Roy D., Liehr J.G. The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology 1993, 132:577.
45. Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U. S. A 1996, 93:3294.
46. Rogan E.G., Badawi A.F., Devanesan P.D., Meza J.L., Edney J.A., West W.W., Higginbotham S.M., Cavalieri E.L. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003, 24:697.
47. Malins D.C., Holmes E.H., Polissar N.L., Gunselman S.J. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 1993, 71:3036.
48. Okoh V., Felty Q., Roy D. Activation of PI3K/AKT Signaling Pathway Is Involved in 4-Hydroxyestradiol-Induced Cell Transformation. The Toxicologist 2007, 96:381. Abstract Nr. 1844.
49. Okoh V., Garba N.A., Felty Q., Roy D. Inhibition of Estrogen-Induced Growth of Breast Cancer Cells by Modulating in Situ Oxidant Levels, [abstract]. Proceeding of Era of Hope, Abstract nr BC051097, June 25-28, baltimore MD 2008, 576.
50. Okoh V., Garba N.A., Felty Q., Roy D. NRF-1 Signaling Participates in the Estrogen-Mediated Growth of Breast Cancer Cells, [abstract]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR); Abstract nr 3360, Apr 18-22, Denver, CO. Philadelphia (PA) 2009.
51. Roy D., Felty Q., Slingerland J.M., Garba N.A., Penny R., koh V. Reversible Inactivation of CDC25A by Estrogen and Antiestrogens-Induced Reactive Oxygen Species May Be Involved in the Phosphorylatopn of P27 2008, 1075.
52. Russo J., Tahin Q., Lareef M.H., Hu Y.F., Russo I.H. Neoplastic transformation of human breast epithelial cells by estrogens and chemical carcinogens. Environ. Mol. Mutagen. 2002, 39:254.
53. Cuendet M., Liu X., Pisha E., Li Y., Yao J., Yu L., Bolton J.L. Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression. Mutat. Res. 2004, 550:109.
54. Li J.J., Li S.A., Oberley T.D., Parsons J.A. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. Cancer Res. 1995, 55:4347.
55. Liu S., Lin Y.C. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17beta. Breast J. 2004, 10:514.
56. Fishman J., Martucci C. Biological properties of 16 alpha-hydroxyestrone: implications in estrogen physiology and pathophysiology. J. Clin. Endocrinol. Metab 1980, 51:611.
57. Zhu B.T., Liehr J.G. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J. Biol. Chem. 1996, 271:1357.
58. Emons G., Merriam G.R., Pfeiffer D., Loriaux D.L., Ball P., Knuppen R. Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. J. Steroid Biochem. 1987, 28:499.
59. Banerjee M.R. Responses of mammary cells to hormones. Int. Rev. Cytol. 1976, 47:1.
60. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 1993, 15:17.
61. Andersen T.I., Heimdal K.R., Skrede M., Tveit K., Berg K., Borresen A.L. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum. Genet. 1994, 94:665.
62. Zeps N., Bentel J.M., Papadimitriou J.M., D'Antuono M.F., Dawkins H.J. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 1998, 62:221.
63. Wiesen J.F., Young P., Werb Z., Cunha G.R. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999, 126:335.
64. Cunha G.R., Young P., Hom Y.K., Cooke P.S., Taylor J.A., Lubahn D.B. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J. Mammary. Gland. Biol. Neoplasia. 1997, 2:393.
65. Sainsbury J.R., Farndon J.R., Sherbet G.V., Harris A.L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985, 1:364.
66. DuMond J.W., Singh K.P., Roy D. Regulation of the growth of mouse Leydig cells by the inactive stereoisomer, 17alpha-estradiol: Lack of correlation between the elevated expression of ERalpha and difference in sensitivity to estradiol isomers. Oncol. Rep. 2001, 8:899.
67. Newbold R.R., Liehr J.G. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res. 2000, 60:235.
68. Colerangle J.B., Roy D. Profound effects of the weak environmental estrogen-like chemical bisphenol A on the growth of the mammary gland of Noble rats. J. Steroid Biochem. Mol. Biol. 1997, 60:153.
69. Holland M.B., Roy D. Estrone-induced cell proliferation and differentiation in the mammary gland of the female Noble rat. Carcinogenesis 1995, 16:1955.
70. Matsumoto Y. Study on the estrogen production in parenchymatous cells of epithelial ovarian tumor. Osaka City Med. J. 1992, 38:27.
71. Moats R.K., Ramirez V.D. Rapid uptake and binding of estradiol-17beta-6-(O-carboxymethyl)oxime:125I-labeled BSA by female rat liver. Biol. Reprod. 1998, 58:531.
72. Monje P., Boland R. Subcellular distribution of native estrogen receptor alpha and beta isoforms in rabbit uterus and ovary. J. Cell Biochem. 2001, 82:467.
73. Chen J.Q., Delannoy M., Cooke C., Yager J.D. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am. J. Physiol Endocrinol. Metab 2004, 286:E1011-E1022.
74. Chen J.Q., Eshete M., Alworth W.L., Yager J.D. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J. Cell Biochem. 2004, 93:358.
75. Felty Q., Roy D. Mitochondrial signals to nucleus regulate estrogen-induced cell growth. Med. Hypotheses 2005, 64:133.
76. Garcia M.V., Cabezas J.A., Perez-Gonzalez M.N. Effects of oestradiol, testosterone and medroxyprogesterone on subcellular fraction marker enzyme activities from rat liver and brain. Comp Biochem. Physiol B 1985, 80:347.
77. Kipp J.L., Ramirez V.D. Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine. 2001, 15:165.
78. Larsson N.G., Wang J., Wilhelmsson H., Oldfors A., Rustin P., Lewandoski M., Barsh G.S., Clayton D.A. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet. 1998, 18:231.
79. Scarpulla R.C. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 2002, 286:81.
80. Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., Mootha V., Troy A., Cinti S., Lowell B., Scarpulla R.C., Spiegelman B.M. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115.
81. Kressler D., Schreiber S.N., Knutti D., Kralli A. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J. Biol. Chem. 2002, 277:13918.
82. Knutti D., Kaul A., Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol. Cell Biol. 2000, 20:2411.
83. Kain K.H., Popov V.L., Herzog N.K. Alterations in mitochondria and mtTFA in response to LPS-induced differentiation of B-cells. Biochim. Biophys. Acta 2000, 1494:91.
84. Casas F., Daury L., Grandemange S., Busson M., Seyer P., Hatier R., Carazo A., Cabello G., Wrutniak-Cabello C. Endocrine regulation of mitochondrial activity: involvement of truncated RXRalpha and c-Erb Aalpha1 proteins. FASEB J. 2003, 17:426.
85. Donahue R.J., Razmara M., Hoek J.B., Knudsen T.B. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J. 2001, 15:635.
86. Liu G., Schwartz J.A., Brooks S.C. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 1999, 264:359.
87. Steinschneider A., Rao M.C., Khan I., McLean M.P., Gibori G. Calcium-calmodulin and calcium-phospholipid dependent phosphorylation of membranous fraction proteins related to the tropic regulation by estradiol in the corpus luteum. Endocrinology 1991, 128:263.
88. Miranda-Vizuete A., Damdimopoulos A.E., Spyrou G. The mitochondrial thioredoxin system. Antioxid. Redox. Signal. 2000, 2:801.
89. Woo H.A., Kang S.W., Kim H.K., Yang K.S., Chae H.Z., Rhee S.G. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J. Biol. Chem. 2003, 278:47361.
90. Lee H.C., Yin P.H., Chi C.W., Wei Y.H. Increase in mitochondrial mass in human fibroblasts under oxidative stress and during replicative cell senescence. J. Biomed. Sci. 2002, 9:517.
91. Nisoli E., Clementi E., Paolucci C., Cozzi V., Tonello C., Sciorati C., Bracale R., Valerio A., Francolini M., Moncada S., Carruba M.O. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003, 299:896.
92. Malins D.C., Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res. 1991, 51:5430.
93. Musarrat J., rezina-Wilson J., Wani A.A. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur. J. Cancer 1996, 32A:1209.
94. Yamamoto T., Hosokawa K., Tamura T., Kanno H., Urabe M., Honjo H. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels in women with or without gynecologic cancer. J. Obstet. Gynaecol. Res. 1996, 22:359.
95. Du M.Q., Carmichael P.L., Phillips D.H. Induction of activating mutations in the human c-Ha-ras-1 proto-oncogene by oxygen free radicals. Mol. Carcinog. 1994, 11:170.
96. Hussain S.P., Hofseth L.J., Harris C.C. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001, 34(Suppl 2):S7.
97. Alworth L.C., Howdeshell K.L., Ruhlen R.L., Day J.K., Lubahn D.B., Huang T.H., Besch-Williford C.L., vom Saal F.S. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. Toxicol. Appl. Pharmacol. 2002, 183:10.
98. Hmadcha A., Bedoya F.J., Sobrino F., Pintado E. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. 1999, 190:1595.
99. Zhu W., Smart E.J. Caveolae, estrogen and nitric oxide. Trends Endocrinol. Metab 2003, 14:114.
100. Suh Y.A., Arnold R.S., Lassegue B., Shi J., Xu X., Sorescu D., Chung A.B., Griendling K.K., Lambeth J.D. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999, 401:79.
101. Aoki F., Choi T., Mori M., Yamashita M., Nagahama Y., Kohmoto K. A deficiency in the mechanism for p34cdc2 protein kinase activation in mouse embryos arrested at 2-cell stage. Dev. Biol. 1992, 154:66.
102. Mailand N., Falck J., Lukas C., Syljuasen R.G., Welcker M., Bartek J., Lukas J. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288:1425.
103. Falck J., Mailand N., Syljuasen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842.
104. Finkel T. Reactive oxygen species and signal transduction. IUBMB. Life 2001, 52:3.
105. Sohn J., Rudolph J. Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction. Biochemistry 2003, 42:10060.
106. Savitsky P.A., Finkel T. Redox regulation of Cdc25C. J. Biol. Chem. 2002, 277:20535.
107. Barrett W.C., DeGnore J.P., Keng Y.F., Zhang Z.Y., Yim M.B., Chock P.B. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J. Biol. Chem. 1999, 274:34543.
108. Boveris A., Cadenas E. Lung Biology in Health and Disease 1997, Marcel Dekker, New York.
109. Tomko R.J., Lazo J.S. Multimodal control of Cdc25A by nitrosative stress. Cancer Res. 2008, 68:7457.
110. Barre B., Vigneron A., Coqueret O. The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J. Biol. Chem. 2005, 280:15673.
111. Melchheier I., von M.C., Stuhlmann D., Sies H., Klotz L.O. Quinone-induced Cdc25A inhibition causes ERK-dependent connexin phosphorylation. Biochem. Biophys. Res. Commun. 2005, 327:1016.
112. Rudolph J. Redox regulation of the Cdc25 phosphatases. Antioxid. Redox. Signal. 2005, 7:761.
113. Wang Z., Zhang B., Wang M., Carr B.I. Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5. J. Cell Physiol 2005, 204:437.
114. Foster J.S., Henley D.C., Ahamed S., Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol. Metab 2001, 12:320.
115. Foster J.S., Henley D.C., Bukovsky A., Seth P., Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol. Cell Biol. 2001, 21:794.
116. Lou Y.W., Chen Y.Y., Hsu S.F., Chen R.K., Lee C.L., Khoo K.H., Tonks N.K., Meng T.C. Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. FEBS J. 2008, 275:69.
117. Isoda M., Kanemori Y., Nakajo N., Uchida S., Yamashita K., Ueno H., Sagata N. The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol. Biol. Cell 2009, 20:2186.
118. Niwa K., Inanami O., Yamamori T., Ohta T., Hamasu T., Kuwabara M. Redox regulation of PI3K/Akt and p53 in bovine aortic endothelial cells exposed to hydrogen peroxide. Antioxid. Redox. Signal. 2003, 5:713.
119. Salmeen A., Barford D. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid. Redox. Signal. 2005, 7:560.
120. Meng T.C., Lou Y.W., Chen Y.Y., Hsu S.F., Huang Y.F. Cys-Oxidation of Protein Tyrosine Phosphatases: Its Role in Regulation of Signal Transduction and Its Involvement in Human Cancers. Journal of Cancer Molecule 2006, 2:9.
121. Golden T., Aragon I.V., Rutland B., Tucker J.A., Shevde L.A., Samant R.S., Zhou G., Amable L., Skarra D., Honkanen R.E. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim. Biophys. Acta 2008, 1782:259.
122. Cui Y., Parra I., Zhang M., Hilsenbeck S.G., Tsimelzon A., Furukawa T., Horii A., Zhang Z.Y., Nicholson R.I., Fuqua S.A. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006, 66:5950.
123. Thomson M. Evidence of undiscovered cell regulatory mechanisms: phosphoproteins and protein kinases in mitochondria. Cell Mol. Life Sci. 2002, 59:213.
124. Baines C.P., Song C.X., Zheng Y.T., Wang G.W., Zhang J., Wang O.L., Guo Y., Bolli R., Cardwell E.M., Ping P. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ. Res. 2003, 92:873.
125. Wu X., Noh S.J., Zhou G., Dixon J.E., Guan K.L. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J. Biol. Chem. 1996, 271:3265.
126. Weinstein-Oppenheimer C.R., Burrows C., Steelman L.S., McCubrey J.A. The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol. Ther. 2002, 1:256.
127. Li L., Lorenzo P.S., Bogi K., Blumberg P.M., Yuspa S.H. Protein kinase Cdelta targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol. Cell Biol. 1999, 19:8547.
128. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870.
129. Chen N., Nomura M., She Q.B., Ma W.Y., Bode A.M., Wang L., Flavell R.A., Dong Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 2001, 61:3908.
130. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3:420.
131. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649.
132. Filardo E.J., Quinn J.A., Frackelton A.R., Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 2002, 16:70.
133. Improta-Brears T., Whorton A.R., Codazzi F., York J.D., Meyer T., McDonnell D.P. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. U. S. A 1999, 96:4686.
134. Kleuser B., Malek D., Gust R., Pertz H.H., Potteck H. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol. Pharmacol. 2008, 74:1533.
135. Bulayeva N.N., Gametchu B., Watson C.S. Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids 2004, 69:181.
136. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab 2009, 20:477.
137. Levin E.R. Rapid signaling by steroid receptors. Am. J. Physiol Regul. Integr. Comp Physiol 2008, 295:R1425-R1430.
138. Dechering K., Boersma C., Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind?. Curr. Med. Chem. 2000, 7:561.
139. Migliaccio A., Di D.M., Castoria G., de F.A., Bontempo P., Nola E., Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15:1292.
140. Endoh H., Sasaki H., Maruyama K., Takeyama K., Waga I., Shimizu T., Kato S., Kawashima H. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun. 1997, 235:99.
141. Watters J.J., Campbell J.S., Cunningham M.J., Krebs E.G., Dorsa D.M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138:4030.
142. Lieberherr M., Grosse B., Kachkache M., Balsan S. Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors. J. Bone Miner. Res. 1993, 8:1365.
143. Razandi M., Pedram A., Greene G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 1999, 13:307.
144. Loomis A.K., Thomas P. Effects of estrogens and xenoestrogens on androgen production by Atlantic croaker testes in vitro: evidence for a nongenomic action mediated by an estrogen membrane receptor. Biol. Reprod. 2000, 62:995.
145. Kar S., Wang M., Yao W., Michejda C.J., Carr B.I. PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 2006, 5:1511.
146. Wu F.Y., Sun T.P. Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase. Eur. J. Cancer 1999, 35:1388.
147. Stauffer F., Holzer P., Garcia-Echeverria C. Blocking the PI3K/PKB pathway in tumor cells. Curr. Med. Chem. Anticancer Agents 2005, 5:449.
148. Barnett S.F., Bilodeau M.T., Lindsley C.W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem. 2005, 5:109.
149. Piantadosi C.A., Suliman H.B. Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. J. Biol. Chem. 2006, 281:324.
150. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V., Cheng J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61:5985.
151. Lee Y.R., Park J., Yu H.N., Kim J.S., Youn H.J., Jung S.H. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 2005, 336:1221.
152. Banerjee S., Saxena N., Sengupta K., Banerjee S.K. 17alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochem. Biophys. Res. Commun. 2003, 300:209.
153. Gao N., Nester R.A., Sarkar M.A. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol. Appl. Pharmacol. 2004, 196:124.
154. Millward T.A., Zolnierowicz S., Hemmings B.A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci. 1999, 24:186.
155. Baldin V., Theis-Febvre N., Benne C., Froment C., Cazales M., Burlet-Schiltz O., Ducommun B. PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation. Biol. Cell 2003, 95:547.
156. Kim H.J., Kang S.K., Mun J.Y., Chun Y.J., Choi K.H., Kim M.Y. Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog. FEBS Lett. 2003, 555:217.
157. Hirose Y., Katayama M., Mirzoeva O.K., Berger M.S., Pieper R.O. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 2005, 65:4861.
158. Fuhrmann G., Leisser C., Rosenberger G., Grusch M., Huettenbrenner S., Halama T., Mosberger I., Sasgary S., Cerni C., Krupitza G. Cdc25A phosphatase suppresses apoptosis induced by serum deprivation. Oncogene 2001, 20:4542.
159. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 2001, 11:173.
160. Tamir S., Izrael S., Vaya J. The effect of oxidative stress on ERalpha and ERbeta expression. J. Steroid Biochem. Mol. Biol. 2002, 81:327.
161. Yau C., Benz C.C. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Res. 2008, 10:R61.
162. Korichneva I., Hoyos B., Chua R., Levi E., Hammerling U. Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. J. Biol. Chem. 2002, 277:44327.
163. Korichneva I. Redox regulation of cardiac protein kinase C. Exp. Clin. Cardiol. 2005, 10:256.
164. Kim S.K., Woodcroft K.J., Oh S.J., Abdelmegeed M.A., Novak R.F. Role of mechanical and redox stress in activation of mitogen-activated protein kinases in primary cultured rat hepatocytes. Biochem. Pharmacol. 2005, 70:1785.
165. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160:1.
166. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 2003, 17:309.
167. Dos Santos E.G., Dieudonne M.N., Pecquery R., Le M.V., Giudicelli Y., Lacasa D. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 2002, 143:930.
168. Bozinovski S., Jones J.E., Vlahos R., Hamilton J.A., Anderson G.P. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J. Biol. Chem. 2002, 277:42808.
169. Manna S.K., Zhang H.J., Yan T., Oberley L.W., Aggarwal B.B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J. Biol. Chem. 1998, 273:13245.
170. Pinkus R., Weiner L.M., Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J. Biol. Chem. 1996, 271:13422.
171. Li W.C., Wang G.M., Wang R.R., Spector A. The redox active components H2O2 and N-acetyl-L-cysteine regulate expression of c-jun and c-fos in lens systems. Exp. Eye Res. 1994, 59:179.
172. Stauble B., Boscoboinik D., Tasinato A., Azzi A. Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and D-alpha-tocopherol in vascular smooth muscle cells. Eur. J. Biochem. 1994, 226:393.
173. Uchida K., Shiraishi M., Naito Y., Torii Y., Nakamura Y., Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J. Biol. Chem. 1999, 274:2234.
174. Parola M., Robino G., Marra F., Pinzani M., Bellomo G., Leonarduzzi G., Chiarugi P., Camandola S., Poli G., Waeg G., Gentilini P., Dianzani M.U. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J. Clin. Invest 1998, 102:1942.
175. Wisdom R. AP-1: one switch for many signals. Exp. Cell Res. 1999, 253:180.
176. Minden A., Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1997, 1333:F85.
177. Okazaki K., Sagata N. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J. 1995, 14:5048.
178. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087.
179. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 1996, 74:589.
180. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 1997, 9:240.
181. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. Philos. Trans. R. Soc. Lond B Biol. Sci. 1996, 351:127.
182. Karin M., Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem. Sci. 1992, 17:418.
183. Fuchs S.Y., Dolan L., Davis R.J., Ronai Z. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 1996, 13:1531.
184. Abate C., Patel L., Rauscher F.J., Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990, 249:1157.
185. Klatt P., Molina E.P., De Lacoba M.G., Padilla C.A., Martinez-Galesteo E., Barcena J.A., Lamas S. Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J. 1999, 13:1481.
186. Xanthoudakis S., Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 1992, 11:653.
187. Schenk H., Klein M., Erdbrugger W., Droge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc. Natl. Acad. Sci. U. S. A 1994, 91:1672.
188. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. U. S. A 1997, 94:3633.
189. Zhang P., Wang Y.Z., Kagan E., Bonner J.C. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J. Biol. Chem. 2000, 275:22479.
190. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596.
191. Gotoh Y., Cooper J.A. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J. Biol. Chem. 1998, 273:17477.
192. Janssen Y.M., Matalon S., Mossman B.T. Differential induction of c-fos, c-jun, and apoptosis in lung epithelial cells exposed to ROS or RNS. Am. J. Physiol 1997, 273:L789-L796.
193. Suliman H.B., Carraway M.S., Welty-Wolf K.E., Whorton A.R., Piantadosi C.A. Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1. J. Biol. Chem. 2003, 278:41510.
194. Adler V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104.
195. Planas-Silva M.D., Donaher J.L., Weinberg R.A. Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Res. 1999, 59:4788.
196. Burdon R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 1995, 18:775.
197. Honore S., Kovacic H., Pichard V., Briand C., Rognoni J.B. Alpha2beta1-integrin signaling by itself controls G1/S transition in a human adenocarcinoma cell line (Caco-2): implication of NADPH oxidase-dependent production of ROS. Exp. Cell Res. 2003, 285:59.
198. Gupta A., Rosenberger S.F., Bowden G.T. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 1999, 20:2063.
199. Turpaev K.T. Reactive oxygen species and regulation of gene expression. Biochemistry (Mosc.) 2002, 67:281.
200. Virbasius C.A., Virbasius J.V., Scarpulla R.C. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev. 1993, 7:2431.
201. Solecki D., Bernhardt G., Lipp M., Wimmer E. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J. Biol. Chem. 2000, 275:12453.
202. Liu Y., Niu N., Zhu X., Du T., Wang X., Chen D., Wu X., Gu H.F., Liu Y. Genetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetes. Diabetes 2008, 57:777.
203. Chau C.M., Evans M.J., Scarpulla R.C. Nuclear respiratory factor 1 activation sites in genes encoding the gamma-subunit of ATP synthase, eukaryotic initiation factor 2 alpha, and tyrosine aminotransferase. Specific interaction of purified NRF-1 with multiple target genes. J. Biol. Chem. 1992, 267:6999.
204. Lee H.C., Yin P.H., Lu C.Y., Chi C.W., Wei Y.H. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem. J. 2000, 348(Pt 2):425.
205. Miranda S., Foncea R., Guerrero J., Leighton F. Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells. Biochem. Biophys. Res. Commun. 1999, 258:44.
206. Mattingly K.A., Ivanova M.M., Riggs K.A., Wickramasinghe N.S., Barch M.J., Klinge C.M. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol. Endocrinol. 2008, 22:609.
207. Ivanova M.M., Mazhawidza W., Dougherty S.M., Minna J.D., Klinge C.M. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol. Cell Endocrinol. 2009, 305:12.
208. Gomez-Cabrera M.C., Domenech E., Romagnoli M., Arduini A., Borras C., Pallardo F.V., Sastre J., Vina J. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am. J. Clin. Nutr. 2008, 87:142.
209. Dai D.F., Santana L.F., Vermulst M., Tomazela D.M., Emond M.J., MacCoss M.J., Gollahon K., Martin G.M., Loeb L.A., Ladiges W.C., Rabinovitch P.S. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 2009, 119:2789.
210. Mobley J.A., Brueggemeier R.W. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004, 25:3.
211. Patel M.M., Bhat H.K. Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: Involvement of metabolic activation and cytochrome P450. J. Biochem. Mol. Toxicol. 2004, 18:37.
212. Jeng J.H., Kuo M.Y., Lee P.H., Wang Y.J., Lee M.Y., Lee J.J., Lin B.R., Tai T.F., Chang M.C. Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes. Toxicology 2006, 223:235.
213. Liu Q., Shimoyama T., Suzuki K., Umeda T., Nakaji S., Sugawara K. Effect of sodium butyrate on reactive oxygen species generation by human neutrophils. Scand. J. Gastroenterol. 2001, 36:744.
214. Izumi H., Ohta R., Nagatani G., Ise T., Nakayama Y., Nomoto M., Kohno K. p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem. J. 2003, 373:713.
215. Kherrouche Z., De Launoit Y., Monte D. The NRF-1/alpha-PAL transcription factor regulates human E2F6 promoter activity. Biochem. J. 2004, 383:529.
216. Fernando R.I., Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol. Biol. Cell 2004, 15:3266.
217. Fan M., Yan P.S., Hartman-Frey C., Chen L., Paik H., Oyer S.L., Salisbury J.D., Cheng A.S., Li L., Abbosh P.H., Huang T.H., Nephew K.P. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006, 66:11954.
218. Fernandez S.V., Russo I.H., Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int. J. Cancer 2006, 118:1862.
219. Suliman H.B., Carraway M.S., Tatro L.G., Piantadosi C.A. A new activating role for CO in cardiac mitochondrial biogenesis. J. Cell Sci. 2007, 120:299.
220. Byun H.O., Kim H.Y., Lim J.J., Seo Y.H., Yoon G. Mitochondrial dysfunction by complex II inhibition delays overall cell cycle progression via reactive oxygen species production. J. Cell Biochem. 2008, 104:1747.
221. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. U. S. A 2005, 102:5992.
222. Knowles H.J., Harris A.L. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res. 2001, 3:318.
223. Duran H.A., de Rey B.M. Differential oxidative stress induced by two different types of skin tumor promoters, benzoyl peroxide and 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 1991, 12:2047.
224. Yano T., Ishikawa G., Ichikawa T. Oxidative stress as a modulating factor of pulmonary tumorigenesis in mice; comparative study on two different strains. Comp Biochem. Physiol C. 1993, 104:407.
225. Tas F., Hansel H., Belce A., Ilvan S., Argon A., Camlica H., Topuz E. Oxidative stress in breast cancer. Med. Oncol. 2005, 22:11.
226. Lieberthal J.G., Kaminsky M., Parkhurst C.N., Tanese N. The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells. Breast Cancer Res. 2009, 11:R42.
227. Schiff R., Reddy P., Ahotupa M., Coronado-Heinsohn E., Grim M., Hilsenbeck S.G., Lawrence R., Deneke S., Herrera R., Chamness G.C., Fuqua S.A., Brown P.H., Osborne C.K. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. 2000, 92:1926.
228. Behrend L., Henderson G., Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 2003, 31:1441.
229. Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003, 15:247.
230. Guyton K.Z., Kensler T.W. Oxidative mechanisms in carcinogenesis. Br. Med. Bull. 1993, 49:523.
231. Klaunig J.E., Xu Y., Bachowski S., Ketcham C.A., Isenberg J.S., Kolaja K.L., Baker T.K., Walborg E.F., Stevenson D.E. Oxidative stress in nongenotoxic carcinogenesis. Toxicol. Lett. 1995, 82-83:683.
232. Kang D.H. Oxidative stress, DNA damage, and breast cancer. AACN. Clin. Issues 2002, 13:540.
233. Xia C., Meng Q., Liu L.Z., Rojanasakul Y., Wang X.R., Jiang B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007, 67:10823.
234. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 2004, 44:239.
235. Yan T., Oberley L.W., Zhong W., St Clair D.K. Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res. 1996, 56:2864.
236. Li J.J., Oberley L.W., St Clair D.K., Ridnour L.A., Oberley T.D. Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 1995, 10:1989.
237. Church S.L., Grant J.W., Ridnour L.A., Oberley L.W., Swanson P.E., Meltzer P.S., Trent J.M. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. U. S. A 1993, 90:3113.
238. Melov S., Coskun P., Patel M., Tuinstra R., Cottrell B., Jun A.S., Zastawny T.H., Dizdaroglu M., Goodman S.I., Huang T.T., Miziorko H., Epstein C.J., Wallace D.C. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc. Natl. Acad. Sci. U. S. A 1999, 96:846.
239. Slanger T.E., Chang-Claude J., Wang-Gohrke S. Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifiers, and risk of breast cancer in a German population. Cancer Causes Control 2006, 17:1025.
240. Wang S., Wang F., Shi X., Dai J., Peng Y., Guo X., Wang X., Shen H., Hu Z. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur. J. Cancer 2009, 45:2874.
241. Cai Q., Shu X.O., Wen W., Cheng J.R., Dai Q., Gao Y.T., Zheng W. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res. 2004, 6:R647-R655.
242. Egan K.M., Thompson P.A., Titus-Ernstoff L., Moore J.H., Ambrosone C.B. MnSOD polymorphism and breast cancer in a population-based case-control study. Cancer Lett. 2003, 199:27.
243. Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U. S. A 1996, 93:3294.
244. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002, 82:47.
245. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 2001, 31:1287.
246. Kim M.R., Chang H.S., Kim B.H., Kim S., Baek S.H., Kim J.H., Lee S.R., Kim J.R. Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell proliferation. Biochem. Biophys. Res. Commun. 2003, 304:119.
247. Maruyama T., Sachi Y., Furuke K., Kitaoka Y., Kanzaki H., Yoshimura Y., Yodoi J. Induction of thioredoxin, a redox-active protein, by ovarian steroid hormones during growth and differentiation of endometrial stromal cells in vitro. Endocrinology 1999, 140:365.
248. Serviddio G., Loverro G., Vicino M., Prigigallo F., Grattagliano I., Altomare E., Vendemiale G. Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J. Clin. Endocrinol. Metab 2002, 87:2843.
249. Choi J.H., Kim T.N., Kim S., Baek S.H., Kim J.H., Lee S.R., Kim J.R. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002, 22:3331.
250. Lee S.Y., Andoh T., Murphy D.L., Chiueh C.C. 17beta-estradiol activates ICI 182, 780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB J. 2003, 17:947.
251. Strehlow K., Rotter S., Wassmann S., Adam O., Grohe C., Laufs K., Bohm M., Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ. Res. 2003, 93:170.
252. Pawitan Y., Bjohle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., Liu E.T., Miller L., Nordgren H., Ploner A., Sandelin K., Shaw P.M., Smeds J., Skoog L., Wedren S., Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7:R953-R964.
253. Elkon R., Linhart C., Sharan R., Shamir R., Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res. 2003, 13:773.
254. Blum R., Elkon R., Yaari S., Zundelevich A., Jacob-Hirsch J., Rechavi G., Shamir R., Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007, 67:3320.
255. Cam H., Balciunaite E., Blais A., Spektor A., Scarpulla R.C., Young R., Kluger Y., Dynlacht B.D. A common set of gene regulatory networks links metabolism and growth inhibition. Mol. Cell 2004, 16:399.
256. Niida A., Smith A.D., Imoto S., Tsutsumi S., Aburatani H., Zhang M.Q., Akiyama T. Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. BMC. Bioinformatics. 2008, 9:404.
257. Ramaswamy S., Tamayo P., Rifkin R., Mukherjee S., Yeang C.H., Angelo M., Ladd C., Reich M., Latulippe E., Mesirov J.P., Poggio T., Gerald W., Loda M., Lander E.S., Golub T.R. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U. S. A 2001, 98:15149.
258. Landis M.D., Seachrist D.D., Montanez-Wiscovich M.E., Danielpour D., Keri R.A. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 2005, 24:5173.
259. Macleod K.F. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. Nat. Rev. Cancer 2008, 8:769.
260. Ngwenya S., Safe S. Cell context-dependent differences in the induction of E2F-1 gene expression by 17 beta-estradiol in MCF-7 and ZR-75 cells. Endocrinology 2003, 144:1675.
261. Efiok B.J., Safer B. Transcriptional regulation of E2F-1 and eIF-2 genes by alpha-pal: a potential mechanism for coordinated regulation of protein synthesis, growth, and the cell cycle. Biochim. Biophys. Acta 2000, 1495:51.
262. Muller H., Bracken A.P., Vernell R., Moroni M.C., Christians F., Grassilli E., Prosperini E., Vigo E., Oliner J.D., Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001, 15:267.
263. Johnson D.G., Cress W.D., Jakoi L., Nevins J.R. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. U. S. A 1994, 91:12823.
264. Tsantoulis P.K., Gorgoulis V.G. Involvement of E2F transcription factor family in cancer. Eur. J. Cancer 2005, 41:2403.
265. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996, 85:537.
266. Pierce A.M., Schneider-Broussard R., Gimenez-Conti I.B., Russell J.L., Conti C.J., Johnson D.G. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell Biol. 1999, 19:6408.
267. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002, 16:245.
268. Ishida S., Huang E., Zuzan H., Spang R., Leone G., West M., Nevins J.R. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol. Cell Biol. 2001, 21:4684.
269. Gaubatz S., Wood J.G., Livingston D.M. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc. Natl. Acad. Sci. U. S. A 1998, 95:9190.
270. Chen C., Wells A.D. Comparative analysis of E2F family member oncogenic activity. PLoS. One. 2007, 2:e912.
271. Stender J.D., Frasor J., Komm B., Chang K.C., Kraus W.L., Katzenellenbogen B.S. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol. Endocrinol. 2007, 21:2112.
272. Piantadosi C.A., Carraway M.S., Babiker A., Suliman H.B. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ. Res. 2008, 103:1232.
273. Morrish F., Giedt C., Hockenbery D. c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. 2003, 17:240.
274. Rodriguez-Pena A., Escriva H., Handler A.C., Vallejo C.G. Thyroid hormone increases transcription of GA-binding protein/nuclear respiratory factor-2 alpha-subunit in rat liver. FEBS Lett. 2002, 514:309.
275. Klinge C.M. Estrogenic control of mitochondrial function and biogenesis. J. Cell Biochem. 2008, 105:1342.
276. Ramachandran B., Yu G., Gulick T. Nuclear respiratory factor 1 controls myocyte enhancer factor 2A transcription to provide a mechanism for coordinate expression of respiratory chain subunits. J. Biol. Chem. 2008, 283:11935.
277. Cox D.M., Du M., Marback M., Yang E.C., Chan J., Siu K.W., McDermott J.C. Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A. J. Biol. Chem. 2003, 278:15297.
278. Li J., Yang J.G., Li W., Du R., Gui L., Tian L., Guo Q.H. Study on novel mutations of MEF2A gene in Chinese patients with coronary artery disease. Zhonghua Yi. Xue. Yi. Chuan Xue. Za Zhi. 2006, 23:265.
279. Yuan H., Lu H.W., Hu J., Chen S.H., Yang G.P., Huang Z.J. MEF2A gene and susceptibility to coronary artery disease in the Chinese people. Zhong. Nan. Da. Xue. Xue. Bao. Yi. Xue. Ban. 2006, 31:453.
280. Bai X., Wu L., Liang T., Liu Z., Li J., Li D., Xie H., Yin S., Yu J., Lin Q., Zheng S. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:83.
281. Wang C., Li Z., Lu Y., Du R., Katiyar S., Yang J., Fu M., Leader J.E., Quong A., Novikoff P.M., Pestell R.G. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc. Natl. Acad. Sci. U. S. A 2006, 103:11567.
282. Sakamaki T., Casimiro M.C., Ju X., Quong A.A., Katiyar S., Liu M., Jiao X., Li A., Zhang X., Lu Y., Wang C., Byers S., Nicholson R., Link T., Shemluck M., Yang J., Fricke S.T., Novikoff P.M., Papanikolaou A., Arnold A., Albanese C., Pestell R. Cyclin D1 determines mitochondrial function in vivo. Mol. Cell Biol. 2006, 26:5449.
283. Castro-Rivera E., Samudio I., Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 2001, 276:30853.
284. Sabbah M., Courilleau D., Mester J., Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U. S. A 1999, 96:11217.
285. Martinez M.C., Post J.A., Verkleij A.J., Verrips C.T., Boonstra J. The effect of hydrogen peroxide on the cyclin D expression in fibroblasts. Cell Mol. Life Sci. 2001, 58:990.
286. Han S., Park K., Bae B.N., Kim K.H., Kim H.J., Kim Y.D., Kim H.Y. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat. 2003, 82:11.
287. Kouvaraki M., Gorgoulis V.G., Rassidakis G.Z., Liodis P., Koutroumbi E., Markopoulos C., Gogas J., Kittas C. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors. Anticancer Res. 2001, 21:991.
288. Kouvaraki M., Gorgoulis V.G., Rassidakis G.Z., Liodis P., Markopoulos C., Gogas J., Kittas C. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer 2002, 94:2454.
289. Zacharatos P., Kotsinas A., Evangelou K., Karakaidos P., Vassiliou L.V., Rezaei N., Kyroudi A., Kittas C., Patsouris E., Papavassiliou A.G., Gorgoulis V.G. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J. Pathol. 2004, 203:744.
290. Zhang S.Y., Liu S.C., Al-Saleem L.F., Holloran D., Babb J., Guo X., Klein-Szanto A.J. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol. Biomarkers Prev. 2000, 9:395.
291. Oberley M.J., Inman D.R., Farnham P.J. E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9. J. Biol. Chem. 2003, 278:42466.
292. Scully R., Xie A. BRCA1 and BRCA2 in breast cancer predisposition and recombination control. J. Mammary. Gland. Biol. Neoplasia. 2004, 9:237.
293. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., Xu J., Goldberg I.D., Jaiswal A.K., Rosen E.M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64:7893.
294. Asangani I.A., Rasheed S.A., Leupold J.H., Post S., Allgayer H. NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1 (CAPNS1) gene. Gene 2008, 410:197.
295. Carragher N.O., Fonseca B.D., Frame M.C. Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. Neoplasia 2004, 6:53.
296. Demarchi F., Schneider C. The calpain system as a modulator of stress/damage response. Cell Cycle 2007, 6:136.
297. Chang W.T., Huang A.M. Alpha-Pal/NRF-1 regulates the promoter of the human integrin-associated protein/CD47 gene. J. Biol. Chem. 2004, 279:14542.
298. Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W.J., Inghirami G., Giancotti F.G. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489.
299. Watanabe A. Cloning and characterization of the promoter region of the bovine membrane tethering protein p115 gene and its regulation in mammary epithelial cells. Biochim. Biophys. Acta 2003, 1629:60.
300. Baar K., Song Z., Semenkovich C.F., Jones T.E., Han D.H., Nolte L.A., Ojuka E.O., Chen M., Holloszy J.O. Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity. FASEB J. 2003, 17:1666.
301. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829.
302. Wegner S.A., Ehrenberg P.K., Chang G., Dayhoff D.E., Sleeker A.L., Michael N.L. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J. Biol. Chem. 1998, 273:4754.
303. Myers S.J., Peters J., Huang Y., Comer M.B., Barthel F., Dingledine R. Transcriptional regulation of the GluR2 gene: neural-specific expression, multiple promoters, and regulatory elements. J. Neurosci. 1998, 18:6723.
304. Izumi H., Ohta R., Nagatani G., Ise T., Nakayama Y., Nomoto M., Kohno K. p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem. J. 2003, 373:713.
305. Kumari D., Gabrielian A., Wheeler D., Usdin K. The roles of Sp1, Sp3, USF1/USF2 and NRF-1 in the regulation and three-dimensional structure of the Fragile X mental retardation gene promoter. Biochem. J. 2005, 386:297.
306. Fu J., Zhang J., Jin F., Patchefsky J., Braunewell K.H., Klein-Szanto A.J. Promoter regulation of the visinin-like subfamily of neuronal calcium sensor proteins by nuclear respiratory factor-1. J. Biol. Chem. 2009, 284:27577.
307. Braunewell K.H. The darker side of Ca2+ signaling by neuronal Ca2+-sensor proteins: from Alzheimer's disease to cancer. Trends Pharmacol. Sci. 2005, 26:345.
308. Gonzalez Guerrico A.M., Jaffer Z.M., Page R.E., Braunewell K.H., Chernoff J., Klein-Szanto A.J. Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene 2005, 24:2307.
309. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323.
310. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004, 7:97.
311. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2:252.
312. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest 1996, 98:2572.
313. Shen J., Platek M., Mahasneh A., Ambrosone C.B., Zhao H. Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion 2010, 10:62.
314. Tesarova P., Kalousova M., Trnkova B., Soukupova J., Argalasova S., Mestek O., Petruzelka L., Zima T. Carbonyl and oxidative stress in patients with breast cancer-is there a relation to the stage of the disease?. Neoplasma 2007, 54:219.
315. Zhang S., Yang X., Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 2004, 65:1208.
316. Alvero A.B., O'Malley D., Brown D., Kelly G., Garg M., Chen W., Rutherford T., Mor G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006, 106:599.
317. Chiao T.B., Lee A.J. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann. Pharmacother. 2005, 39:516.
318. Sanchiz F., Milla A., Artola N., Julia J.C., Moya L.M., Pedro A., Vila A. Prevention of radioinduced cystitis by orgotein: a randomized study. Anticancer Res. 1996, 16:2025.
319. Drisko J.A., Chapman J., Hunter V.J. The use of antioxidant therapies during chemotherapy. Gynecol. Oncol. 2003, 88:434.
320. Camphausen K., Citrin D., Krishna M.C., Mitchell J.B. Implications for tumor control during protection of normal tissues with antioxidants. J. Clin. Oncol. 2005, 23:5455.
321. Conklin K.A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr. Cancer 2000, 37:1.
322. Paiva S.A., Russell R.M. Beta-carotene and other carotenoids as antioxidants. J. Am. Coll. Nutr. 1999, 18:426.
323. D'Andrea G.M. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J. Clin. 2005, 55:319.
324. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., Lee C.H., Lim S.J. Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J. Control Release 2005, 107:43.
325. Roninson I.B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem. Pharmacol. 1992, 43:95.
326. Trock B.J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 1997, 89:917.
327. Nagaoka R., Iwasaki T., Rokutanda N., Takeshita A., Koibuchi Y., Horiguchi J., Shimokawa N., Iino Y., Morishita Y., Koibuchi N. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine 2006, 30:261.
328. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., Magnusen J.E. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell Endocrinol. 2010, 323:268.
329. Shareef M.M., Brown B., Shajahan S., Sathishkumar S., Arnold S.M., Mohiuddin M., Ahmed M.M., Spring P.M. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells. Mol. Cancer Res. 2008, 6:89.
330. Knutsen T., Mickley L.A., Ried T., Green E.D., du M.S., Schrock E., Macville M., Ning Y., Robey R., Polymeropoulos M., Torres R., Fojo T. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL, Genes Chromosomes. Cancer 1998, 23:44.
331. van V., Dai H., d.van V., He Y.D., Hart A.A., Mao M., Peterse H.L., van der K.K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530.